Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Final decisions on matters not referred to an expert advisory committee
1. New Chemical Entities - medicines for human therapeutic use
1.3 Risankizumab
Delegate's final decision
The delegate's final decision under regulation 42ZCZU of the Therapeutic Goods Regulations 1990 is to include risankizumab in Schedule 4 and Appendix K of the Poisons Standard as follows:
Schedule 4 - New Entry
RISANKIZUMAB.
Appendix K - New Entry
RISANKIZUMAB
Index - New Entry
RISANKIZUMAB
Schedule 4
Appendix K
Implementation date
1 October 2019
Reasons
The matters under subsection 52E(1) of the Therapeutic Goods Act 1989 considered relevant by the delegate for the decision include:
- the risks and benefits of the use of a substance:
- It is a new chemical entity with no clinical or marketing experience in Australia.
- the purposes for which a substance is to be used and the extent of use of a substance:
- Moderate to severe plaque psoriasis.
- the toxicity of a substance:
- Potential toxicity is unknown.
- the dosage, formulation, labelling, packaging and presentation of a substance:
- Substance requires subcutaneous injection.
- the potential for abuse of a substance:
- Nil.
- any other matters that the Secretary considers necessary to protect public health:
- Nil.
Scheduling proposal
The delegate of the Secretary proposed to amend the Poisons Standard with respect to risankizumab, a new chemical entity (NCE) for a human therapeutic medicine.
Scheduling status
Risankizumab is not specifically scheduled in the Poisons Standard, but as a monoclonal antibody, it is captured by the Schedule 4 entry for monoclonal antibodies as follows:
Schedule 4
MONOCLONAL ANTIBODIES for therapeutic use except:
- in diagnostic test kits; or
- when separately specified in these Schedules.
Delegate's considerations
- Advice on the place in therapy of this NCE;
- Scheduling Policy Framework (SPF 2018); and
- Section 52E(1) of the Therapeutic Goods Act 1989 in particular: (a) the risks and benefits of the use of a substance; (b) the purposes for which a substance is to be used and the extent of use of a substance; (c) the toxicity of a substance; and (d) the dosage, formulation, labelling, packaging and presentation of a substance.